Planner
Xiao Liu: Vice President, CoJourney; Chief Brand Officer, TONACEA

09:30-09:35　Opening Remarks
Xiao Liu: Vice President, CoJourney; Chief Brand Officer, TONACEA

09:35-09:50　Round-robin Interview
Yuan Cai (Host): Head of AAV, Metabolic Health Lab, Shanda Group
Xiao Xiao: Chairman, Belief BioMed
Zhenhua Wu: Founder, Chairman & CEO, Exegenesis Bio
Jingmin Zhou: Co-Founder & CEO, Genemagic Biosciences
Fenghua Wang: Founder, Chairman & CEO, Innostellar Biotherapeutics
Gong Chen: Founder, NeuExcell Therapeutics
Biao Dong: Founder, Real&Best Biotech

09:50-10:30　Debate: Should Gene Therapy Expand to Broader Indications?
Jiayu Zhang (Pro): Founder & CEO, Juvensis Therapeutics
Yuanyuan Xu (Pro): Chairman, Cure Genetics
Shengjiang Liu (Pro): Chairman & CEO, Avirmax
Chunyan He (Con): Founder & CEO, GenAssist
Kun Wu (Con)
Wei Wang (Con): CEO, Chigenovo

10:30-11:10　Panel Discussion I: The Unshared Joy of Reaching the Industry Summit
Hongyuan Wang (Host)
Piming Zhao
Lijun Wang: Founder & CEO, CoJourney
Zhengbin Li: CEO, Neurophth
Xiao Xiao: Chairman, Belief BioMed
Fenghua Wang: Founder, Chairman & CEO, Innostellar Biotherapeutics

11:10-11:45　Panel Discussion II: Gene Therapy — Boao, 818 or 828
Zhenhua Wu (Host): Founder, Chairman & CEO, Exegenesis Bio
Guang Qu: Co-Founder, NGGT
Biao Dong: Founder, Real&Best Biotech
Yue Chen: Vice President of Business Development, WuXi Atu

11:45-12:30　Panel Discussion III: Surprises in the Future of Gene Therapy
Lijing Chen (Host): COO & Vice President, Genewiz
Lu Gao: CEO, Euhearing Therapeutics
Jingmin Zhou: Co-Founder & CEO, Genemagic Biosciences
Jiayu Zhang: Founder & CEO, Juvensis Therapeutics
Yuanyuan Xu: Chairman, Cure Genetics
Nina Zhang

10:00–10:20　3D Intelligent Manufacturing Technology Empowers Large-Scale Manufacturing of Extracellular Vesicle Drugs
Xiaojun Yan: Co-founder & CTO, CytoNiche

10:20–10:35　CMC Research and Clinical Translation Challenges of Extracellular Vesicle Therapeutics
Hongwu Zhang: Chairman, Shanghai Stexo Biotechnology

10:35-10:50　R&D and Clinical Development of Engineered Exosomes for IND Pathway
Guoying Zhou: Founder, Chairman & CEO, ImmVira

10:50-11:05　The Era of Integrated Medicine Driven by Extracellular Vesicle Technology
Zhentao Li: CEO, Carrier Biomed (Suzhou)

11:05-11:20　Under Order No. 818: Regulatory Landscape and Innovation Pathways of Exosomes
Lei Zhang: CTO, Boyalife Stem Cell

11:20-12:00　Roundtable: Innovative Exosome Drugs from Lab to Clinic: What Are the Biggest Hurdles? (Large-Scale Manufacturing, Quality Standards, Regulatory Pathways, Investment Opportunities and Risks)
Jerry Liu（Moderator ）：Vice President, CoJourney; Chief Brand Officer, TONACEA

Wei Liu：Co-Founder & CEO, CytoNiche
Hongwu Zhang：Chairman, Shanghai Stexo Biotechnology 
Lei Zhang：CTO, Boyalife Stem Cell
Haizi Cheng：Director of R&D, CMC in Charge, Obio Technology

Leo Xu：FE ZENITH CAPITAI Managing Director& Head of Healthcare Investment

09:00-09:20　Personalized Cancer Immunotherapy: Current Status and Future
Bin Li: Researcher, Shanghai Institute of Immunology

09:20-09:35　Strategic Roadmap for Emerging Biopharma Companies Entering the Japanese Market
Motoki FUJII: Senior Official, Regulatory Affairs Division, EPS

09:35-09:50　R&D Landscape, Emerging Trends, and Opportunities in Autoimmune Diseases
Shuona Yuan: Senior Research Analyst, PharmCube

09:50-10:05　Practical Strategies and Case Studies in Global Clinical Development of Novel Oncology Drugs
Shengjun Zhang: General Manager, BioTrialMed

10:05-10:20　From Design to Detection: Precision Screening with End-to-End Guidance
Lei Huang: Head of Translational Medicine, Burning Rock Biotech

10:20-10:40　Break

10:40-10:55　Reshaping Translational R&D Decision-Making for Advanced Therapies and Novel Drug Modalities with QSP Models
Chen Zhao: Professor and Ph.D. Supervisor, Nanjing Medical University; Distinguished Medical Expert of Jiangsu Province

10:55-11:10　Innovative Therapies Session: Next-Generation Fully Humanized Mouse Models Empowering Breakthroughs in Oncology and Autoimmune R&D
Wenxin Liu: Head of Immuno-Oncology Pipeline, GenNovo Biotech

11:10-11:25　Innovative TIL Therapy: Redefining the Treatment Landscape for Solid Tumors
Zhenjiu Wang: CMO, HUASAIBIO

11:25-11:40　The Ways to Enhance Efficacy and Avoid Risks in Preclinical Research of Anti-Tumor and Self Immune New Drugs
Jian Ge: Executive Vice President, Preclinical Research Division, Medicilon

09:00-09:15　Integrated Solutions for Oligonucleotide Therapeutic Development
Haiying He: Vice President, Head of Oligonucleotide & Peptide Discovery Chemistry, WuXi TIDES

09:15-09:30　Bioanalytical Strategies for Pharmacokinetic Assessment of Oligonucleotide Therapeutics
Jinlian Lu: Director, Drug Metabolism and Pharmacokinetics (DMPK), Laboratory Testing Division (LTD), WuXi AppTec

09:30-09:45　CNS Delivery Technologies in Large Animal (Non-Rodent) Species Enable DMPK Studies of Oligonucleotide Therapeutics
Jie Li: Associate Director, Drug Metabolism and Pharmacokinetics (DMPK), Laboratory Testing Division (LTD), WuXi AppTec

09:45-10:00　Nonclinical Safety Evaluation of Oligonucleotide Drugs
Yan Zhang: Director, Toxicology, Laboratory Testing Division (LTD), WuXi AppTec

10:00-10:15　Challenges and Solutions in Clinical Bioanalysis of Novel Oligonucleotide Drugs
Wenzhong Liang: Executive Director, Bioanalysis, Laboratory Testing Division (LTD), WuXi AppTec

10:15-10:30　Coffee Break

10:30-10:45　Efficient Synthesis Strategies for TPD
Anshu Wu: Senior Director, Research Chemistry Services, WuXi Chemistry, WuXi AppTec

10:45-11:00　Key Points and Safety Evaluation in Nonclinical Design of TPD
Robert Zhang: Vice President, Head of Toxicology, Laboratory Testing Division (LTD), WuXi AppTec

11:00-11:15　Integrated Solutions for PROTAC Development
Yu Lu: Vice President of API Early Phase Process R&D, WuXi STA

11:15-12:00　Roundtable
TBD (More guests to be confirmed…)

13:30-13:45　Global Innovation Strategy of DualityBio
John Zhu: Chairman, DualityBio

13:45-14:00　Global Collaboration Opportunities and Clinical Progress of Alphamab Oncology's Product Pipeline
Ting Xu: Chairman & President, Alphamab Oncology

14:00-14:15　Restructuring the Value Chain of Antibody and ADCs from Local to Global
Cuiling Song: Senior Application & Product Director, Bailinke

14:15-14:30　Differentiated Clinical Strategies for ADC Global Expansion and Development
Tongtong Xue: CEO, MediLink Therapeutics

14:30-14:45　Global Collaboration Opportunities and Clinical Progress of ImmuneOnco's Product Pipeline
Wenzhi Tian: Founder & Chairman, ImmuneOnco Biopharmaceuticals

14:45-15:00　Beyond Supply: Innovative Toolchains to Systematically Accelerate ADC Development
Xiaojing An: Dean of Sino Biological Innovation Research Institute

15:00-15:15　Innovation Strategy of Lepu Biopharma
Ziye Sui: CEO, Lepu Biopharma

15:15-15:30　Innovation Strategy of 3S Bio
Yanli Liu: General Manager, 3S Bio

15:30-15:45　Antibody Innovation Strategy of Affinity Biopharma
Chen Liu: Founder, President & Co-CMO, Affinity Biopharma

15:45-16:00　Engineering Strategies to Maximize the Efficacy of Antibody-Drug Conjugates
Changshou Gao: CTO, Shanghai Allist Pharmaceuticals

16:00-16:15　Innovation Strategy of Mabwell
Ke Hu: Senior Vice President, Mabwell

16:15-16:30　Precision Modeling Empowers a New Paradigm in Drug R&D: Application Value of Fully Humanized Mouse Models in Preclinical Research
Yuan Dong: R&D Director, China, Genovo Biotech

16:30-16:45　A Global Perspective on ADC Development
Junli Zhang: Senior Vice President, ADC BU Head and MFG Sites Head, Zencore Biologics

16:45-17:00　AI-Driven Precision and Scalability Empowering Next-Generation Dual-Payload ADCs
Yi Yang: CSO, Biocytogen

17:00-17:15　Global Development Strategy of Transcenta Holding's Antibody Drugs
Xueming Qian: CEO, Transcenta Holding

17:15-17:30　Digital-Intelligence Integration: Reconstructing Cell Culture Media and Bioprocess Development
Max Wang: CEO, MediumBank

Meeting Planner
Zicai Liang：Chairman and CEO, Ribo Life Science
Yan Chang：Chairman and President, InnoStar
Howe Li：Chairman, Livius Biotech

July 23

09:00-09:30   The Third Wave of Modern Pharmaceuticals – From the Prosperity of Hepatic Delivery to the Surging Advance of Extrahepatic Delivery in Small Nucleic Acid Pharmaceuticals
Zicai Liang：Chairman and CEO, Ribo Life Science

09:30-09:50   Differentiated Project Initiation and Pipeline Layout Strategies for Small Nucleic Acid Drugs Based on Disease Mechanisms
Dong Xie：Chairman 、CEO 、CSO, Frontier Biotechnologies Inc.

09:50-10:10   Applications and Progress of siRNA Drugs in the Field of Lipid Management
Lianshan Zhang：Director & Executive Vice President, Hengrui Medicine

10:10-10:30   Dual-Target Oligonucleotides Enable Novel Therapeutic Strategies for Comorbid Metabolic Disorders
Xinjian Liu：CSO & Vice President,  BeBetter Med Inc.

10:30-11:00   Break

11:00-11:15   Development of antisense oligonucleotides for HBV cure
Chris Yang：Co-founder & CSO, AusperBio

11:15-12:00   Roundtable Discussion: The Next Five Years of the Small Nucleic Acid Drug Industry
Quan Gan (Moderator)：Managing Director, SDIC Investment
Zicai Liang：Chairman and CEO, Ribo Life Science
Dong Xie：Chairman, CEO & CSO, Frontier Biotechnologies Inc.
Dongxu Shu：Founder, Chairman & CEO, Argo Biopharma
Xin Xie：Executive Director & Senior Vice President, Sino Biopharmaceutical
Nannan Chang：Managing Director, GL Ventures

12:00-13:00   Lunch

13:00-13:15   Developing a New Generation of siRNA Drugs Centered on AI
Xiangrui Gao：Head of Nucleic Acid Drug R&D, XtalPi

13:15-13:30   TBD
Qian Li:Chairman, Beijing Sun-novo Pharmaceutical Research

13:30-13:45   siRNA: Reshaping the Therapeutic Landscape of Chronic Diseases
Qunsheng Ji:CEO, Sirius Therapeutics

13:45-14:00   siRNA vs ASO: Two Paths of Oligonucleotide Innovation for Chronic Hepatitis B
Qing Zhu:Senior Vice President,Brii Bio

14:00-14:15   Toxicological Evaluation of Small Nucleic Acid Drugs: Key Considerations and Case Analysis
Naping Tang:Vice President, InnoStar

14:15-14:30   How Anlong Biotech Stands Out in the Small Nucleic Acid Industry
Chunlin Zhao:Founder, AnlongBio; Founding Partner, Anlong Fund

14:30-14:45   Development and Application of Small Nucleic Acid Drugs in the Cardiovascular Field
Xiaoming Zou:CEO, Bisirna Therapeutics

14:45-15:00   Breakthrough in delivery platform advances the application of small nucleic acid drugs in chronic diseases
Lijuan Wang:CSO, Shenzhen Salubris Pharmaceuticals

15:00-15:20   Coffee Break

15:20-15:35   Extrahepatic Delivery and Clinical Research of Small Nucleic Acid Drugs
Yuanyu Huang:Founder & Chairman, Rigerna Therapeutics

15:35-15:50   Novel Cross-Modal Drug R&D Technologies Based on Small Nucleic Acids
Xingquan Ma:Co-President, ChemPartner

15:50-16:05   Early Clinical Trial Design and Safety Evaluation of Nucleic Acid Drugs
Ruihua Dong:Director of Clinical Research Ward, Beijing Friendship Hospital, Capital Medical University

16:05-16:20   Systematic Solutions for Small Nucleic Acids: From Lab-Scale Trials to Commercial Production
Yanhua Wang:Product Director, Small Nucleic Acid Solution Division, Tofflon

16:20-16:35   Neural Mouse Models: Bridging Preclinical Efficacy to Clinical Outcomes
Shuxin Xu:Deputy Director of Preclinical Service Platform, Head of Metabolism Pipeline & Chief Scientist of Metabolism, GemPharmatech

16:35-16:50   Antisense makes sense
Haisheng Wang:Founder & CEO, SicaGene

16:50-17:30   Roundtable Discussion: Technical Challenges and Breakthroughs of Small Nucleic Acid Drugs
Hao Li (Moderator):Chairman, Livius Biotech
Xiaobin Zhao:Founder, Chairman & General Manager, HaiChang Biotech
Xiaoye Su:Dean of Research Institute, CSPC Pharmaceutical Group
Haizhou Zhang:Senior Vice President, GeneScience Pharmaceuticals (Changchun)
Yun Zhu:General Manager, YUN HO BIO
 Hu Xiaomin：Former Senior Pharmacist/Senior Reviewer at CDE (Center for Drug Evaluation)

July 24

09:00-09:15   MicroRNA (miRNA) Therapies for Aging-Related Diseases
Hao Li:Chairman, Livius Biotech

09:15-09:30   Beyond the Liver: SCAD and LiCO—Clinically Validated Extrahepatic Delivery Platforms for Oligonucleotide Therapeutics
Longcheng Li:Founder, Chairman & CEO, Ractigen Therapeutics

09:30-09:45   Innovative siRNA Therapeutics for Pulmonary Diseases
Yi Huang:General Manager, Innovative Drug Division, Gowell Pharmaceutical

09:45-10:00   Introduction to Sirnaomics’ GalAhead Delivery Platform and Clinical Progress of STP122G
Weiwei Tian:VP, Sirnaomics

10:00-10:15   Overview of Youcare Pharmaceutical’s Oligonucleotide Innovation Platform and R&D Pipeline
Gengshen Song:Director, Deputy General Manager & Dean of Pharmaceutical Research Institute, Youcare Pharmaceutical Group Co.,Ltd.

10:15-10:30   AI-Driven Targeted RNA Therapeutics Platform
Rong Xin:CEO, RecoRNA

10:30-10:50   Break

10:50-11:05   Conjugation Empowerment: Delivery Advancements & Multi-Target Hurdles for Next-Generation siRNA Drugs
Chengjiang Zhao:Co-Founder, Youjia Biotech

11:05-11:20   From bench to bed –case study of siRNA drugs for metabolism/CVD
Jinqiao Wan:Chairman CEO ,Leaderna

11:20-12:00   Roundtable Discussion: Innovation of Small Nucleic Acid Drugs from the Investor's Perspective
Fei Qi (Moderator):Executive Director, Legend Capital
Zhiping Cui:General Manager, New Drug Fund, Fosun Health Capital; Chairman, Hepa Thera
Li Wang:Member of Investment Banking Committee & Head of Healthcare Department, Guotai Haitong Securities
Junhong Li:Partner, Lapam Capital
Wei Ding:Partner, Apricot Capital

12:00-13:00   Lunch

13:00-13:15   Extrahepatic Targeted Delivery Technologies Based on lncRNA
Xu Song:Founder, lncTAC

13:15-13:30   Oligonucleotide Drug Development: Translational Barriers and Clinical Countermeasures in First-in-Human Trials and Proof-of-Concept Studies
Junlong Wang:General Manager, InnoClinic

13:30-13:45   Small Nucleic Acids, Grand Era — Global Industrial Transformation and the Empowerment Journey of Cytiva
Yi Zhu:Gene Therapy Technology Lead, Cytiva China

13:45-14:00   Extreme Manufacturing and Its Applications in Nucleotide Monomer Synthesis
Fang Zhao:Research Professor, East China Normal University

14:00-14:15   CMC Research of Nucleic Acid Therapeutics: Manufacturing and Quality Control from Starting Phosphoramidite Monomers to Drug Substances
Qing Li:CEO, Tianjin Pharma, Desano Group

14:15-14:30   Development of Nucleic Acid Drugs Based on Novel Nucleic Acid Modifications and Exploration of Ophthalmic Applications
Chuan Zhang:Founder & CEO, Rehydration Therapeutics

14:30-14:45    Analytical Characterization Challenges and Solutions for Nucleic Acid Medicines
Lei Ma:Biopharmaceutical Application Specialist, Waters